Levamlodipine
As of the edition of 20 October 2026, Levamlodipine is a small molecule: marketed, first approved in 2019 (US); acts on CACNA1C, CACNA1D and CACNA1F and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Conjupri
- First approved
- 19 December 2019 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Cspc
- Registered trials
- 19, 0 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Levamlodipine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 1 | 1 | 0 |
| Phase 4 | 5 | 3 | 0 | 0 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Cspc | Originator and Lead sponsor of trials | 2019 to now |